Win For Pfizer? Seagen's Cancer Combo Therapy Hits Primary Goal In Late-Stage Breast Cancer Study
Portfolio Pulse from Vandana Singh
Seagen Inc announced that its Phase 3 HER2CLIMB-02 clinical trial of Tukysa in combination with Kadcyla met its primary endpoint of progression-free survival. Pfizer Inc has agreed to acquire Seagen in a $43 billion deal to gain access to its targeted cancer therapies. Seagen's shares are down 0.11% at $193.98.
August 16, 2023 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Seagen's Phase 3 clinical trial of Tukysa met its primary endpoint. However, the company's shares are down 0.11%.
The successful trial of Tukysa is a positive development for Seagen. However, the slight drop in the company's share price indicates that the market has not yet fully reacted to this news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer has agreed to acquire Seagen in a $43 billion deal to gain access to its targeted cancer therapies.
The acquisition of Seagen will provide Pfizer with access to targeted cancer therapies, which could potentially boost its product portfolio and revenues in the future.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 80